The UK government confirmed on 19 November 2026 that it will update the legal definition of gene therapy medicines, according to a GOV.UK announcement. The change is meant to let some lab-made gene therapies and newer genome-editing products be overseen within the framework the country already uses for advanced therapies.
The plans are set out in the government's reply to a consultation run jointly by the Department of Health in Northern Ireland and the Medicines and Healthcare products Regulatory Agency (MHRA). Some 83% of those who took part backed the proposals. The Human Medicines Regulations 2012 would then be amended, but only once parliament gives its approval and international notification steps have been completed.
How classification would work
Under the revised rules, the government says, a product would count as a gene therapy medicinal product (GTMP) if it meets either of two criteria. One is that its active ingredient carries a recombinant or synthetic nucleic acid that is transcribed or translated. The other is that it works by editing the genome at a specific sequence. Satisfying one of these would be sufficient. The government describes this as a more technologically neutral approach that stays consistent with established principles for advanced therapy medicinal products (ATMPs).
According to the government, the route to approval and the bar for safety, quality and efficacy will not change. Products that are already licensed will keep their current classification.
Why the old wording falls short
The government says the UK's ATMP definitions date from 2007, a period when treatments relied on fewer technologies. Therapies today may draw on lab-made genetic material, newer methods of editing genomes and heavily engineered cells and tissues, and many may be hard to place within the groupings laid down in the 2012 regulations.
Julian Beach, the MHRA's Executive Director Operations, said the proposals would fill a gap in the present definition and give developers a clearer licensing route. He said greater certainty could help attract investment and strengthen the UK's standing in life sciences.
Consultation and timing
The MHRA opened the six-week, UK-wide consultation on 11 May 2026, and it closed on 22 June 2026. Patient groups, NHS bodies, universities, professional organisations and drug and biotech firms all sent responses, and these were broadly in favour. The MHRA will now take forward the necessary legislation.
The announcement came at the first DIA-MHRA Global Summit, staged in London on 16–17 November 2026 during London Life Sciences Week. The MHRA and the Drug Information Association (DIA) co-hosted the event.






